Clinical Trial Update: The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis [Phase 2]

View source ↗

Summary

The Phase 2 TELO-SCOPE study evaluating danazol to attenuate telomere attrition in pulmonary fibrosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyskeratosis Congenita
• Pulmonary Fibrosis
• Telomere Biology Disorders

Drugs mentioned

• Danazol (danazol)

Snippet

Sponsor: The University of Queensland | Conditions: Pulmonary Fibrosis, Telomere Shortening | Phase 2 | Status: TERMINATED